• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

AB Blood Group is Associated with Cognitive Impairment

September 26, 2014

tx_news_26_septIn a recent case-controlled study published in Neurology, researchers assessed the relationship between ABO blood group, factor VIII, and the incident cognitive impairment.

Compared to blood group O, blood group AB individuals had an increased risk of cognitive decline after adjusting for age, race, religion, and sex (odds ratio=1.82, 95% CI=1.15-2.90) and had higher factor VIII plasma levels. Factor VIII accounted for less than 20% of the association between AB blood group and cognitive impairment. Further studies are needed to define the relationship and underlying mechanisms between cognitive impairment and blood type.

Reference

1. Alexander KS, Zakai NA, Gillett S, McClure LA, Wadley V, Unverzagt F, Cushman M. ABO blood type, factor VIII, and incident cognitive impairment in the REGARDS cohort. Neurology 2014.

Filed Under

  • News
  • Serology/Genotyping

Recommended

  • Drone Delivery of Blood Products in South Africa

  • FDA Guidance for COVID-19 Convalescent Plasma to Remain in Effect

  • Convalescent Plasma for COVID-19 Safe in First 5,000 Patients

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Phosphatidylserine and Phosphatidylethanolamine Levels on RBCs Important for Transfusion Outcomes

  • Blood Donation and Improved Cardiometabolic Health

  • Mitochondrial DNA Acts as a “First Hit” for Antibody-Mediated TRALI

  • Liberal or Restrictive Transfusion Thresholds for Surgery Patients with High Cardiac Risk

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley